roflumilast
astrazeneca,arcutis biotherapeutics
['integument-1', 'roflumilast', 'integument-2', 'derm']
lawrence f. eichenfield, md of &amp; spoke at #aad2023 about the integument-1 and integument-2 studies on roflumilast for atopic dermatitis. check out this interview segment here: #eczema #roflumilast #aad23
Clinical News for Connected Physicians. Everything you need to enhance your clinical approach to improving patient care.